181114-98-7

Basic information

• Product Name: 1-BENZYL-4-METHYL-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 1-BENZYL-4-METHYL-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER;Methyl (3S,4S)-1-benzyl-4-methylpyrrolidine-3-carboxylate;(3S,4S)-Methyl 1-benzyl-4-methylpyrrolidine-3-carboxylate;EOS-62037
• CAS NO: 181114-98-7
• Molecular Formula: C₁₄H₁₉NO₂
• Molecular Weight: 233.31
• Product Categories: pharmacetical
• Mol File: 181114-98-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-BENZYL-4-METHYL-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-4-METHYL-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER(181114-98-7)
• EPA Substance Registry System: 1-BENZYL-4-METHYL-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER(181114-98-7)

Safety Data

• Hazardous Substances Data: 181114-98-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
1-BENZYL-4-METHYL-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER is used as a building block for the synthesis of novel drugs due to its unique chemical structure and potential biological activity. It aids in the exploration of new therapeutic agents and contributes to the understanding of structure-activity relationships in existing pharmaceuticals.
Used in Drug Discovery:
In the drug discovery process, 1-BENZYL-4-METHYL-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER is used as a starting point for the development of new pharmaceutical compounds. Its chemical properties and potential interactions with biological targets make it a valuable candidate for further investigation and optimization.
Used in Medicinal Chemistry:
1-BENZYL-4-METHYL-PYRROLIDINE-3-CARBOXYLIC ACID METHYL ESTER is utilized in medicinal chemistry for studying the structure-activity relationships of pharmaceuticals. This helps in the design and modification of drug molecules to enhance their efficacy, selectivity, and safety.
Note: Since the provided materials do not specify different industries or detailed applications, the uses listed are generalized within the context of pharmaceutical research and development. Further information would be required to delineate specific applications in various industries.

Upstream product

• 67-56-1 methanol 
• 604798-83-6 (3S,4S)-1-benzyl-4-methylpyrrolidine-3-carboxylic acid 
• 189506-93-2 (R)-3-((3S,4S)-1-benzyl-4-methylpyrrolidine-3-carbonyl)-4-phenyloxazolidin-2-one 
• 623-43-8 methyl crotonate 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 

Downstream Products

• 1369514-75-9 2-((3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl)-7-(tetrahydro-2H-pyran-4-yl)-imidazo[1,5-f][1,2,4]triazin-4(3H)-one 
• 1369515-41-2 2-((3-((3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)methyl)isoindoline-1,3-dione 
• 1369515-42-3 6-(aminomethyl)-3-((3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl)-1,2,4-triazin-5(4H)-one 
• 1369515-43-4 N-((3-((3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)methyl)tetrahydro-2H-pyran-4-carboxamide 
• 1082743-70-1 6-((3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 604798-83-6 (3S,4S)-1-benzyl-4-methylpyrrolidine-3-carboxylic acid 

Relevant articles and documents

Heterocyclic phosphodiesterase inhibitor and uses thereof

The present invention belongs to the technical field of medicine, and particularly relates to a heterocyclic phosphodiesterase inhibitor compound represented by a formula (I), or a pharmaceutically acceptable salt and a stereoisomer thereof, and a pharmaceutical preparation, a pharmaceutical composition and applications of the compound, wherein R1, R2, R3, R4, ring A, m and n are defined in the specification. According to the present invention, the compound can be used for preparing drugs for treatment or prevention of diseases associated with PDE9 kinase.

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including CNS or neurodegeneration disorder.